Biomedical Research Education & Training
Faculty Member

Hulgan, Todd, M.D., M.P.H.
Associate Professor of Medicine

Lab Url: N/A

Phone Number:

Email Address:

Hulgan, Todd's picture
Academic history
B.S., University of South Alabama
M.D., University of Alabama School of Medicine (UAB)
M.P.H., Vanderbilt University

Office Address   Mailing Address

S-2115 MCN

A2200 MCN Vanderbilt University 37232-2582

Clinical Research Keywords
HIV/AIDS; antiretroviral therapy; mitochondrial genomics; oxidant stress; drug abuse

Patient Care Specialty
Adult Infectious Diseases/HIV/Immunosuppressed populations

Research Specialty
Clinical outcomes/translational HIV research; antiretroviral toxicity; mitochondrial genomics and oxidant stress

Clinical Research Description
The primary goals of my research are to: 1) expand our understanding of the role of genetic variation in mitochondrial DNA (mtDNA) in outcomes of HIV infection and treatments; and 2) to characterize relevant biomarkers of adverse outcomes in treated HIV-infected persons. This work includes collaborations with the AIDS Clinical Trials Group (ACTG), the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) group, and multi-disciplinary teams of investigators including clinical pharmacologists, biostatisticians, mitochondrial geneticists, and computational biologists/geneticists. My projects bridge epidemiology-outcomes and clinical-translational research domains.

Koethe, JR, Bian, A, Shintani, AK, Wester, CW, Erdem, H, Hulgan, T. An association between adiposity and serum levels of macrophage inflammatory protein-1?? and soluble CD14 in HIV-infected adults: results from a cross-sectional study. Antivir Ther, 2013

Koethe, JR, Dee, K, Bian, A, Shintani, A, Turner, M, Bebawy, S, Sterling, TR, Hulgan, T. Circulating Interleukin-6, Soluble CD14, and Other Inflammation Biomarker Levels Differ Between Obese and Nonobese HIV-Infected Adults on Antiretroviral Therapy. AIDS Res Hum Retroviruses, 2013

Rasbach, DA, Desruisseau, AJ, Kipp, AM, Stinnette, S, Kheshti, A, Shepherd, BE, Sterling, TR, Hulgan, T, McGowan, CC, Qian, HZ. Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: use of a rapid screening tool during routine clinic visits. AIDS Care, 25(1), 109-17, 2013

Holzinger, ER, Hulgan, T, Ellis, RJ, Samuels, DC, Ritchie, MD, Haas, DW, Kallianpur, AR, Bloss, CS, Clifford, DB, Collier, AC, Gelman, BB, Marra, CM, McArthur, JC, McCutchan, JA, Morgello, S, Simpson, DM, Franklin, DR, Rosario, D, Selph, D, Letendre, S, Grant, I, , . Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol, 18(6), 511-20, 2012

Hulgan, T, Robbins, GK, Kalams, SA, Samuels, DC, Grady, B, Shafer, R, Murdock, DG, Selph, D, Haas, DW, Pollard, RB, , . T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384. PLoS One, 7(8), e43803, 2012

Koethe, JR, Bian, A, Shintani, AK, Boger, MS, Mitchell, VJ, Erdem, H, Hulgan, T. Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy. AIDS Res Hum Retroviruses, 28(6), 552-7, 2012

Grady, BJ, Samuels, DC, Robbins, GK, Selph, D, Canter, JA, Pollard, RB, Haas, DW, Shafer, R, Kalams, SA, Murdock, DG, Ritchie, MD, Hulgan, T, , . Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384. J Acquir Immune Defic Syndr, 58(4), 363-70, 2011

Haas, DW, Kuritzkes, DR, Ritchie, MD, Amur, S, Gage, BF, Maartens, G, Masys, D, Fellay, J, Phillips, E, Ribaudo, HJ, Freedberg, KA, Petropoulos, C, Manolio, TA, Gulick, RM, Haubrich, R, Kim, P, Dehlinger, M, Abebe, R, Telenti, A, , . Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials, 12(5), 277-85, 2011

Hulgan, T, Haubrich, R, Riddler, SA, Tebas, P, Ritchie, MD, McComsey, GA, Haas, DW, Canter, JA. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS, 25(1), 37-47, 2011 PMCID:3081810

McGowan, CC, Weinstein, DD, Samenow, CP, Stinnette, SE, Barkanic, G, Rebeiro, PF, Sterling, TR, Moore, RD, Hulgan, T. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One, 6(4), e18462, 2011 PMCID:3081810

Qian, HZ, Stinnette, SE, Rebeiro, PF, Kipp, AM, Shepherd, BE, Samenow, CP, Jenkins, CA, No, P, McGowan, CC, Hulgan, T, Sterling, TR. The relationship between injection and noninjection drug use and HIV disease progression. J Subst Abuse Treat, 41(1), 14-20, 2011 PMCID:3081810

Alves, TP, Hulgan, T, Wu, P, Sterling, TR, Stinnette, SE, Rebeiro, PF, Vincz, AJ, Bruce, M, Ikizler, TA. Race, kidney disease progression, and mortality risk in HIV-infected persons. Clin J Am Soc Nephrol, 5(12), 2269-75, 2010 PMCID:3081810

Canter, JA, Robbins, GK, Selph, D, Clifford, DB, Kallianpur, AR, Shafer, R, Levy, S, Murdock, DG, Ritchie, MD, Haas, DW, Hulgan, T. African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J Infect Dis, 201(11), 1703-7, 2010 PMCID:2862090

Melekhin, VV, Shepherd, BE, Jenkins, CA, Stinnette, SE, Rebeiro, PF, Bebawy, SS, Rasbach, DA, Hulgan, T, Sterling, TR. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States. AIDS Patient Care STDS, 24(5), 279-86, 2010 PMCID:2875979

Shepherd, BE, Jenkins, CA, Rebeiro, PF, Stinnette, SE, Bebawy, SS, McGowan, CC, Hulgan, T, Sterling, TR. Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Epidemiology, 21(5), 698-705, 2010 PMCID:3086582

Boger, MS, Shintani, A, Redhage, LA, Mitchell, V, Haas, DW, Morrow, JD, Hulgan, T. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr, 52(4), 480-7, 2009 PMCID:2794651

Hulgan, T, Donahue, JP, Smeaton, L, Pu, M, Wang, H, Lederman, MM, Smith, K, Valdez, H, Pilcher, C, Haas, DW . Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors. Eur J Clin Pharmacol, 2009

Kallianpur, AR, Hulgan, T. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics, 10(4), 623-37, 2009 PMCID:2706211

Lemly, DC, Shepherd, BE, Hulgan, T, Rebeiro, P, Stinnette, S, Blackwell, RB, Bebawy, S, Kheshti, A, Sterling, TR, Raffanti, SP. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis, 199(7), 991-8, 2009

Redhage, LA, Shintani, A, Haas, DW, Emeagwali, N, Markovic, M, Oboho, I, Mwenya, C, Erdem, H, Acosta, EP, Morrow, JD, Hulgan, T. Clinical factors associated with plasma F2-Isoprostane Levels in HIV-Infected Adults. HIV Clin Trials, 10(3), 181-92, 2009

Shepherd, BE, Sterling, TR, Moore, RD, Raffanti, SP, Hulgan, T. Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. J Clin Epidemiol, 62(7), 729-37, 2009 PMCID:2747519

Asad, S, Hulgan, T, Raffanti, SP, Daugherty, J, Ray, W, Sterling, TR. Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors. J Natl Med Assoc, 100(12), 1417-24, 2008

El-Bejjani, D, Hazen, SL, Mackay, W, Glass, NE, Hulgan, T, Tungsiripat, M, McComsey, GA. Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults. HIV Clin Trials, 9(3), 207-11, 2008

Hulgan, T. High-concentration capsaicin reduced pain in patients with HIV-associated polyneuropathy. Evid Based Med, 13(6), 183, 2008

Hulgan, T, Klausner, JD. Phosphodiesterase type-5 inhibitors and the reemerging HIV epidemic. JAMA, 299(12), 1426, 2008

Hulgan, T, Tebas, P, Canter, JA, Mulligan, K, Haas, DW, Dub??, M, Grinspoon, S, Robbins, GK, Motsinger, AA, Kallianpur, AR . Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis, 197(6), 858-66, 2008

Bress, JN, Hulgan, T, Lyon, JA, Johnston, CP, Lehmann, H, Sterling, TR. Agreement of decision analyses and subsequent clinical studies in infectious diseases. Am J Med, 120(5), 461.e1-9, 2007 PMCID:1909755

Canter, JA, Haas, DW, Kallianpur, AR, Ritchie, MD, Robbins, GK, Shafer, RW, Clifford, DB, Murdock, DG, Hulgan, T. The mitochondrial pharmacogenomics of haplogroup T: MTND2(*)LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J, 2007

Hulgan, T, Shepherd, BE, Raffanti, SP, Fusco, JS, Beckerman, R, Barkanic, G, Sterling, TR. Absolute Count and Percentage of CD4+ Lymphocytes Are Independent Predictors of Disease Progression in HIV-Infected Persons Initiating Highly Active Antiretroviral Therapy. J Infect Dis, 195(3), 425-31, 2007

Motsinger, AA, Haas, DW, Hulgan, T, Ritchie, MD. Human genomic association studies: a primer for the infectious diseases specialist. J Infect Dis, 195(12), 1737-44, 2007

Oswald-Richter, K, Grill, SM, Leelawong, M, Tseng, M, Kalams, SA, Hulgan, T, Haas, DW, Unutmaz, D. Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog, 3(4), e58, 2007 PMCID:1857714

Hulgan, T, Haas, DW. Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity. J Infect Dis, 194(11), 1471-4, 2006

Hulgan, T, Hughes, M, Sun, X, Smeaton, LM, Terry, E, Robbins, GK, Shafer, RW, Clifford, DB, McComsey, GA, Canter, JA, Morrow, JD, Haas, DW. Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J Acquir Immune Defic Syndr, 42(4), 450-4, 2006

Kallianpur, AR, Hulgan, T, Canter, JA, Ritchie, MD, Haines, JL, Robbins, GK, Shafer, RW, Clifford, DB, Haas, DW. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS, 20(11), 1503-13, 2006

Hulgan, T, Haas, DW, Haines, JL, Ritchie, MD, Robbins, GK, Shafer, RW, Clifford, DB, Kallianpur, AR, Summar, M, Canter, JA. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS, 19(13), 1341-9, 2005

Hulgan, T, Raffanti, S, Kheshti, A, Blackwell, RB, Rebeiro, PF, Barkanic, G, Ritz, B, Sterling, TR. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis, 192(6), 950-7, 2005

Hulgan, T, Sterling, TR, Daugherty, J, Arbogast, PG, Raffanti, S, Ray, W. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr, 38(3), 277-82, 2005

Chan, SY, Hulgan, T, D''Aquila, RT. The Role of Baseline HIV-1 Resistance Testing in Patients with Established Infection. Curr Infect Dis Rep, 6(3), 243-249, 2004

Haas, DW, Ribaudo, HJ, Kim, RB, Tierney, C, Wilkinson, GR, Gulick, RM, Clifford, DB, Hulgan, T, Marzolini, C, Acosta, EP. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS, 18(18), 2391-400, 2004

Hulgan, T, Rosenbloom, ST, Hargrove, F, Talbert, DA, Arbogast, PG, Bansal, P, Miller, RA, Kernodle, DS. Oral quinolones in hospitalized patients: an evaluation of a computerized decision support intervention. J Intern Med, 256(4), 349-57, 2004

Donahue, JP, Dowdy, D, Ratnam, KK, Hulgan, T, Price, J, Unutmaz, D, Nicotera, J, Raffanti, S, Becker, M, Haas, DW. Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clin Pharmacol Ther, 73(1), 78-86, 2003

Haas, DW, Johnson, BW, Spearman, P, Raffanti, S, Nicotera, J, Schmidt, D, Hulgan, T, Shepard, R, Fiscus, SA. Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Neurology, 61(10), 1391-6, 2003

Hulgan, T, Donahue, JP, Hawkins, C, Unutmaz, D, D''Aquila, RT, Raffanti, S, Nicotera, F, Rebeiro, P, Erdem, H, Rueff, M, Haas, DW. Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy. J Acquir Immune Defic Syndr, 34(2), 119-26, 2003

Hulgan, T, Morrow, J, D''Aquila, RT, Raffanti, S, Morgan, M, Rebeiro, P, Haas, DW. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis, 37(12), 1711-7, 2003

Sherertz, RJ, Ely, EW, Westbrook, DM, Gledhill, KS, Streed, SA, Kiger, B, Flynn, L, Hayes, S, Strong, S, Cruz, J, Bowton, DL, Hulgan, T, Haponik, EF. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann Intern Med, 132(8), 641-8, 2000

Moore, RB, Hulgan, TM, Green, JW, Jenkins, LD. Increased susceptibility of the sickle cell membrane Ca2+ + Mg(2+)-ATPase to t-butylhydroperoxide: protective effects of ascorbate and desferal. Blood, 79(5), 1334-41, 1992

Postdoctoral Position Available

Postdoctoral Position Details

Updated Date